UY31232A1 - COMPOUNDS DERIVED FROM DIBENZOTIFENILAMINO-CROMEN-4-ACTIVE WAVES REPLACED AND ITS ISOMERS AND APPLICATIONS - Google Patents

COMPOUNDS DERIVED FROM DIBENZOTIFENILAMINO-CROMEN-4-ACTIVE WAVES REPLACED AND ITS ISOMERS AND APPLICATIONS

Info

Publication number
UY31232A1
UY31232A1 UY31232A UY31232A UY31232A1 UY 31232 A1 UY31232 A1 UY 31232A1 UY 31232 A UY31232 A UY 31232A UY 31232 A UY31232 A UY 31232A UY 31232 A1 UY31232 A1 UY 31232A1
Authority
UY
Uruguay
Prior art keywords
group
dibenzotifenilamino
cromen
isomers
replaced
Prior art date
Application number
UY31232A
Other languages
Spanish (es)
Inventor
Niall Morrison Barr Martin
Sylvie Gomez
Heather Mary Ellen Duggan
Christine Sarah Bailey
Marc Geoffrey Hummersone
Keith Allan Menear
Frigerio Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31232A1 publication Critical patent/UY31232A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuestos de la formula I, en donde: R1 y R2 se seleccionan de manera independiente entre hidrogeno, un grupo alquilo C1-7, un grupo heterociclilo C3-20 o arilo C5-20 opcionalmente sustituido, o juntos pueden formar, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalemente sustituido que tiene entre 4 y 8 átomos de anillo; X es CH o N; n es 1 o 2; RC1 y Rc2 se seleccionan de manera independiente entre H y metilo; cuando X es N, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido y sulfonilo; y cuando X es CH, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido, sulfonilo, amino y éter.A compound of the formula I, wherein: R1 and R2 are independently selected from hydrogen, a C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, or together they can form, together with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having between 4 and 8 ring atoms; X is CH or N; n is 1 or 2; RC1 and Rc2 are independently selected from H and methyl; when X is N, Rx is selected from the group consisting of H, and an optionally substituted group of C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, acyl, ester, amido and sulfonyl; and when X is CH, Rx is selected from the group consisting of H, and an optionally substituted group of C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, acyl, ester, amido, sulfonyl, amino and ether.

UY31232A 2007-07-19 2008-07-17 COMPOUNDS DERIVED FROM DIBENZOTIFENILAMINO-CROMEN-4-ACTIVE WAVES REPLACED AND ITS ISOMERS AND APPLICATIONS UY31232A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95063107P 2007-07-19 2007-07-19
US3656008P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
UY31232A1 true UY31232A1 (en) 2009-03-02

Family

ID=39791057

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31232A UY31232A1 (en) 2007-07-19 2008-07-17 COMPOUNDS DERIVED FROM DIBENZOTIFENILAMINO-CROMEN-4-ACTIVE WAVES REPLACED AND ITS ISOMERS AND APPLICATIONS

Country Status (14)

Country Link
US (1) US20090042865A1 (en)
EP (1) EP2176254A1 (en)
JP (1) JP2010533694A (en)
KR (1) KR20100063701A (en)
CN (1) CN101754964A (en)
AR (1) AR067613A1 (en)
AU (1) AU2008277418A1 (en)
BR (1) BRPI0814797A2 (en)
CA (1) CA2693926A1 (en)
CL (1) CL2008002130A1 (en)
RU (1) RU2009149210A (en)
TW (1) TW200918528A (en)
UY (1) UY31232A1 (en)
WO (1) WO2009010761A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB2420781B (en) * 2003-08-13 2008-07-09 Kudos Pharm Ltd Aminopyrones and their use as ATM inhibitors
BRPI0515498A (en) * 2004-09-20 2008-07-29 Kudos Pharm Ltd dna-pk inhibitors
WO2006085067A1 (en) * 2005-02-09 2006-08-17 Kudos Pharmaceuticals Limited Atm inhibitors
AR054438A1 (en) * 2005-04-15 2007-06-27 Kudos Pharm Ltd DNA INHIBITORS -PK
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20100033419A (en) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
JP5909185B2 (en) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド Substituted tetrazol-1-ylphenoxymethylthiazol-2-ylpiperidinylpyrimidine salt
WO2011137428A1 (en) * 2010-04-30 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating hiv infection: inhibition of dna dependent protein kinase
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
RS61664B1 (en) 2012-04-24 2021-04-29 Vertex Pharma Dna-pk inhibitors
RS58374B1 (en) 2013-03-12 2019-03-29 Vertex Pharma Dna-pk inhibitors
CN104892589A (en) 2014-03-07 2015-09-09 中国科学院上海药物研究所 Heterocyclic compound, preparation method therefor and use thereof
CN109862896A (en) 2016-08-03 2019-06-07 西玛贝医药公司 For treating the Oxymethylene aryl compound of inflammatory gastrointestinal disease or gastrointestinal disorder
TW201815418A (en) 2016-09-27 2018-05-01 Vertex Pharma Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN111053903A (en) * 2019-12-26 2020-04-24 深圳市纳诺艾医疗科技有限公司 Application of compound of nucleic acid analogue carrying resonance atom
TW202235074A (en) * 2021-01-05 2022-09-16 大陸商山東軒竹醫藥科技有限公司 polycyclic kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (en) * 1987-10-08 1995-06-07 富山化学工業株式会社 4H-1-benzopyran-4-one derivative and its salt, their production method and anti-inflammatory agent containing them
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP4103968B2 (en) * 1996-09-18 2008-06-18 株式会社半導体エネルギー研究所 Insulated gate type semiconductor device
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
JP2004501191A (en) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド Carvedilol
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2420781B (en) * 2003-08-13 2008-07-09 Kudos Pharm Ltd Aminopyrones and their use as ATM inhibitors
BRPI0515498A (en) * 2004-09-20 2008-07-29 Kudos Pharm Ltd dna-pk inhibitors
WO2006085067A1 (en) * 2005-02-09 2006-08-17 Kudos Pharmaceuticals Limited Atm inhibitors
AR054438A1 (en) * 2005-04-15 2007-06-27 Kudos Pharm Ltd DNA INHIBITORS -PK
JP5781720B2 (en) * 2008-12-15 2015-09-24 ルネサスエレクトロニクス株式会社 Semiconductor device and manufacturing method of semiconductor device

Also Published As

Publication number Publication date
CN101754964A (en) 2010-06-23
AR067613A1 (en) 2009-10-14
US20090042865A1 (en) 2009-02-12
KR20100063701A (en) 2010-06-11
CA2693926A1 (en) 2009-01-22
CL2008002130A1 (en) 2009-01-02
EP2176254A1 (en) 2010-04-21
TW200918528A (en) 2009-05-01
JP2010533694A (en) 2010-10-28
RU2009149210A (en) 2011-08-27
AU2008277418A1 (en) 2009-01-22
BRPI0814797A2 (en) 2015-02-03
WO2009010761A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
UY31232A1 (en) COMPOUNDS DERIVED FROM DIBENZOTIFENILAMINO-CROMEN-4-ACTIVE WAVES REPLACED AND ITS ISOMERS AND APPLICATIONS
CL2012000311A1 (en) Derived compounds containing rings with 3 nitrogen atoms; Useful in the treatment of parasitosis in animals.
EA200971100A1 (en) PHTHALASININE DERIVATIVES AS A POLY INHIBITORS (ADP-RIBOSE) POLYMERASE (PARP-1)
JO2947B1 (en) Cyclopamine Analogs
ES2530398T3 (en) 4-substituted pyrrolidin-2-ones and their use
HK1097273A1 (en) Aminopyrones and their use as atm inhibitors
MX2016014238A (en) Cleaning composition.
CO6561817A2 (en) DERIVATIVES OF PIRIDINA DI-REPLACED AS ANTICANCER AGENTS
MY152972A (en) Azabicyclo compound and salt thereof
NO20071873L (en) DNA-PK inhibitors.
EA201171328A1 (en) Derivative Isoquinoline Derivative
AR067691A1 (en) SULFONIMIDOIL HETEROCICLIC DERIVATIVES, PESTICIDED COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME FOR PEST CONTROL.
MX2015007883A (en) Compounds for protection of cells.
MX2010007593A (en) Novel derivatives of acyl cyanopyrrolidines.
MX2016014239A (en) Cleaning composition.
CO6320143A1 (en) NEW DIHYDROINDOLONE DERIVATIVES ITS PHARMACEUTICAL PREPARATION PROCEDURE AND COMPOSITIONS CONTAINING THEM
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
CY1117560T1 (en) NEW SUBSTITUTED ISOKINOLIN PRODUCTION
AR060379A1 (en) COMPOUND AND HERBICIDE COMPOSITION
GB2470170A (en) Dithienothiophene derivatives
ATE528284T1 (en) METAL CARBAMATES FROM TOLYLENEDIAMINES
IN2012DN01251A (en)
ES2546833T3 (en) Pyrrolidine derivatives as NK-3 receptor antagonists
CR20110306A (en) DERIVATIVES OF MORFINA-6-GLUCURONIDO, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MX2009004075A (en) Enantiomer-enriched alpha-,omega amino alcohol derivatives, their production and use as insect- and mite-repelling agents.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171009